Laura Sepp-Lorenzino - Jan 4, 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Scientific Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jan 4, 2023
Transactions value $
-$182,982
Form type
4
Date filed
1/6/2023, 04:39 PM
Previous filing
Jan 4, 2023
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$93.3K -2.51K -11.16% $37.21 20K Jan 4, 2023 Direct F1
transaction NTLA Common Stock Sale -$62.7K -1.64K -8.22% $38.22 18.3K Jan 5, 2023 Direct F2, F3
transaction NTLA Common Stock Sale -$26.9K -689 -3.76% $39.10 17.6K Jan 5, 2023 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.
F2 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.